Skip to main content
Top
Published in: International Urology and Nephrology 12/2023

Open Access 10-05-2023 | Urolithiasis | Nephrology - Review

Measures of frequency and effect in clinical research

Authors: Graziella D’Arrigo, Mercedes Gori, Annalisa Pitino, Dimitrios G. Tsalikakis, Vassilios Liakopoulos, Stefanos Roumeliotis, Giovanni Tripepi

Published in: International Urology and Nephrology | Issue 12/2023

Login to get access

Abstract

The assessment of risk and effect size of a specific endpoint associated to the presence/absence of a certain exposure is a hallmark in clinical and epidemiological research. In fact, before recommending any treatment, it is mandatory to investigate the magnitude of the benefits and harms between the exposure under investigation (e.g. a given treatment) and a specific disease or event. To do this, clinicians and statisticians use absolute (risk differences, number needed to treat, likelihood to be helped or harmed) and relative (risk ratio, incidence rate ratio, hazard ratio and odds ratio) measures of effect. Herein, using a series of clinical examples, we aim to present a step by step methodologic approach of measures of effect in the area of nephrology and urology.
Literature
1.
go back to reference Ranganathan P, Pramesh CS, Aggarwal R (2016) Common pitfalls in statistical analysis absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res 7(1):51–53CrossRefPubMedPubMedCentral Ranganathan P, Pramesh CS, Aggarwal R (2016) Common pitfalls in statistical analysis absolute risk reduction, relative risk reduction, and number needed to treat. Perspect Clin Res 7(1):51–53CrossRefPubMedPubMedCentral
2.
go back to reference Troche JR, Mayne ST, Freedman ND, Shebl FM, Abnet CC (2016) The association between alcohol consumption and lung carcinoma by histological subtype. Am J Epidemiol 183(2):110–121PubMed Troche JR, Mayne ST, Freedman ND, Shebl FM, Abnet CC (2016) The association between alcohol consumption and lung carcinoma by histological subtype. Am J Epidemiol 183(2):110–121PubMed
3.
go back to reference Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340, c332 and Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:869 Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. BMJ. 2010, 340, c332 and Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:869
4.
go back to reference von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann InternMed 2007; 147: 573–577 and Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann InternMed 147:W163–W194 von Elm E, Altman DG, Egger M et al (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann InternMed 2007; 147: 573–577 and Vandenbroucke JP, von Elm E, Altman DG et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann InternMed 147:W163–W194
Metadata
Title
Measures of frequency and effect in clinical research
Authors
Graziella D’Arrigo
Mercedes Gori
Annalisa Pitino
Dimitrios G. Tsalikakis
Vassilios Liakopoulos
Stefanos Roumeliotis
Giovanni Tripepi
Publication date
10-05-2023
Publisher
Springer Netherlands
Keyword
Urolithiasis
Published in
International Urology and Nephrology / Issue 12/2023
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03626-w

Other articles of this Issue 12/2023

International Urology and Nephrology 12/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine